BX-471 Berlex.

Abstract

Berlex and its parent company, Schering AG, are developing BX-471 (also known as ZK-811752), the lead in a series of non-peptide chemokine receptor 1 (CCR1) antagonists, for the potential treatment of autoimmune diseases, in particular multiple sclerosis (MS) [291682], [376290], [411184]. In March 2000, BX-471 was undergoing phase I trials for the potential treatment of autoimmune diseases [362022]; phase I trials in MS were ongoing in March 2002 [441989], [443941]. Positive results from these trials have been reported and Berlex was planning phase II trials in MS patients as of mid-March 2002 [444906]. In July 2001, Schering estimated filing in the US and EU in 2008 [411184], [416493]. WO-09856771 claims piperazinyl derivatives, pharmaceutical compositions comprising them and their use in the treatment of inflammatory conditions.

• Authors: Mariano J Elices
• Journal: Current opinion in investigational drugs (London, England : 2000) (Curr Opin Investig Drugs) Vol. 3 Issue 6 Pg. 865-9 (Jun 2002) ISSN: 1472-4472 [Print] England
• PMID: 12137405 (Publication Type: Journal Article, Review)

Chemical References

• CCR1 protein, human
• Phenylurea Compounds
• Piperidines
• Receptors, CCR1
• Receptors, Chemokine
• BX 471

Topics

• Animals
• Autoimmune Diseases (drug therapy)
• Clinical Trials, Phase I as Topic
• Drug Evaluation, Preclinical
• Graft Rejection (drug therapy)
• Humans
• Multiple Sclerosis (drug therapy)
• Phenylurea Compounds (chemistry, therapeutic use)
• Piperidines (chemistry, therapeutic use)
• Receptors, CCR1
• Receptors, Chemokine (antagonists & inhibitors)
• Structure-Activity Relationship
• Treatment Outcome